<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>MBBS Pathology Notes: Plasma Cell Myeloma</title>
    <link href="https://fonts.googleapis.com/css2?family=Kalam:wght@300;400;700&display=swap" rel="stylesheet">
    <style>
        :root {
            --neon-yellow: #f4ff40; /* Neon yellowish highlighter */
            --marker-green: #daffb3; /* Natural light green marker */
            --ink-color: #2c2c2c; /* Dark grey/black ink look */
            --paper-white: #ffffff; /* Pure white page */
            --box-bg: #fffef0; /* Subtle warm tint for boxes */
            --border-color: #333;
        }

        * {
            box-sizing: border-box;
        }

        body {
            background-color: #525659; /* Grey background behind the paper */
            font-family: 'Kalam', cursive;
            color: var(--ink-color);
            margin: 0;
            padding: 20px;
            display: flex;
            justify-content: center;
            line-height: 1.6;
            font-size: 18px; /* Readable handwritten size */
        }

        /* A4 Paper Simulation */
        .page-container {
            background-color: var(--paper-white);
            width: 210mm; /* A4 width */
            min-height: 297mm; /* A4 height minimum */
            padding: 25mm; /* Standard margins */
            box-shadow: 0 4px 15px rgba(0,0,0,0.3);
            position: relative;
            margin-bottom: 20px;
        }

        /* Typography */
        h1 {
            font-size: 32px;
            text-align: center;
            text-decoration: underline;
            text-decoration-color: var(--neon-yellow);
            text-decoration-thickness: 5px;
            margin-bottom: 40px;
            color: #000;
            text-transform: uppercase;
            letter-spacing: 1px;
        }

        h2 {
            font-size: 26px;
            border-bottom: 3px solid var(--marker-green);
            padding-bottom: 5px;
            margin-top: 40px;
            color: #1a1a1a;
            display: inline-block;
            width: 100%;
        }

        h3 {
            font-size: 22px;
            font-weight: 700;
            margin-top: 25px;
            color: #333;
            text-decoration: underline;
        }

        h4 {
            font-size: 20px;
            font-weight: 700;
            margin-top: 15px;
            color: #444;
        }

        p {
            margin-bottom: 15px;
            text-align: justify;
        }

        ul, ol {
            margin-bottom: 15px;
            padding-left: 25px;
        }

        li {
            margin-bottom: 8px;
        }

        /* Highlighting Classes */
        .highlight-neon {
            background-color: var(--neon-yellow);
            padding: 2px 5px;
            border-radius: 4px;
            font-weight: bold;
        }

        .highlight-green {
            background-color: var(--marker-green);
            padding: 2px 5px;
            border-radius: 4px;
            font-weight: bold;
        }

        strong {
            font-weight: 700;
        }

        /* Hand-drawn Box Style */
        .hand-drawn-box {
            border: 2px solid var(--border-color);
            /* Irregular border radius for hand-drawn effect */
            border-radius: 2px 20px 3px 25px / 25px 3px 20px 2px;
            padding: 20px;
            margin: 25px 0;
            background-color: var(--box-bg); 
            box-shadow: 3px 4px 0px rgba(0,0,0,0.1);
        }

        /* Table Styling */
        table {
            width: 100%;
            border-collapse: separate;
            border-spacing: 0;
            margin: 20px 0;
            font-size: 16px;
            border: 2px solid var(--border-color);
            border-radius: 8px;
            overflow: hidden;
        }

        th, td {
            border-right: 1px solid var(--border-color);
            border-bottom: 1px solid var(--border-color);
            padding: 12px;
            text-align: left;
            vertical-align: top;
        }

        th {
            background-color: var(--marker-green);
            font-weight: bold;
            border-bottom: 2px solid var(--border-color);
        }

        tr:last-child td {
            border-bottom: none;
        }
        
        tr td:last-child, tr th:last-child {
            border-right: none;
        }

        /* Model Answer Section */
        .qa-section {
            border-left: 4px solid var(--neon-yellow);
            padding-left: 20px;
            margin-top: 30px;
        }

        /* Print Settings */
        @media print {
            body {
                background-color: white;
                padding: 0;
            }
            .page-container {
                width: 100%;
                box-shadow: none;
                margin: 0;
                padding: 15mm;
            }
            /* Ensure background colors print */
            * {
                -webkit-print-color-adjust: exact !important;
                print-color-adjust: exact !important;
            }
            h1, h2, h3 {
                page-break-after: avoid;
            }
            table, .hand-drawn-box, li {
                page-break-inside: avoid;
            }
        }

        /* Responsive Mobile */
        @media (max-width: 800px) {
            .page-container {
                width: 100%;
                padding: 15px;
            }
            table {
                font-size: 14px;
                display: block;
                overflow-x: auto;
            }
        }
    </style>
</head>
<body>

<div class="page-container">

    <h1>TOPIC 19: PLASMA CELL MYELOMA</h1>

    <p><strong>Syllabus Scope:</strong> Features of Plasma Cell Myeloma (Multiple Myeloma).</p>

    <h2>1. DEFINITION AND INTRODUCTION</h2>
    
    <p><strong>Definition:</strong> Multiple Myeloma (MM) is a malignant neoplasm of plasma cells that is characterized by the accumulation of clonal plasma cells in the bone marrow, the production of a monoclonal immunoglobulin (M protein) in the serum and/or urine, and associated end-organ damage (CRAB criteria).</p>

    <div class="hand-drawn-box">
        <h3>Key Terminology</h3>
        <ul>
            <li><strong>Monoclonal Gammopathy:</strong> Expansion of a single clone of immunoglobulin-secreting cells.</li>
            <li><strong>M-Protein (Paraprotein):</strong> The monoclonal antibody produced (usually IgG or IgA).</li>
            <li><strong>Bence Jones Protein:</strong> Free light chains (kappa or lambda) excreted in the urine.</li>
        </ul>
    </div>

    <hr>

    <h2>2. PATHOGENESIS</h2>
    <p>The disease typically evolves from a premalignant stage called <strong>MGUS</strong> (Monoclonal Gammopathy of Undetermined Significance).</p>

    <h3>A. Molecular Pathogenesis</h3>
    <ul>
        <li><strong>Genetic Aberrations:</strong> Frequent translocations involving the <strong>IgH locus on Chromosome 14q32</strong> (e.g., t(11;14), t(4;14)). Deletions of 13q and 17p (TP53) are poor prognostic markers.</li>
        <li><strong>Bone Marrow Microenvironment:</strong> Adhesion of myeloma cells to stromal cells triggers the production of cytokines, most importantly <span class="highlight-neon">Interleukin-6 (IL-6)</span>. IL-6 promotes the survival and proliferation of myeloma cells.</li>
    </ul>

    <h3>B. Mechanism of Clinical Features</h3>
    <ol>
        <li><strong>Bone Destruction (Lytic Lesions):</strong> Myeloma cells upregulate <span class="highlight-green">RANKL</span> expression on stromal cells. RANKL activates <strong>Osteoclasts</strong> (bone-eating cells). Simultaneously, they suppress Osteoblasts (bone-forming cells) via Wnt pathway inhibitors. This leads to purely lytic "punched-out" lesions.</li>
        <li><strong>Renal Failure (Myeloma Kidney):</strong> Excess free light chains (Bence Jones proteins) are toxic to renal tubules. They combine with <strong>Tamm-Horsfall protein</strong> in the distal tubules to form obstructing casts. Hypercalcemia also damages the kidney (nephrocalcinosis).</li>
        <li><strong>Immunosuppression:</strong> Suppression of normal plasma cells leads to hypogammaglobulinemia, increasing susceptibility to bacterial infections.</li>
    </ol>

    <hr>

    <h2>3. CLINICAL FEATURES (CRAB CRITERIA)</h2>
    <p>The hallmark manifestations are summarized by the mnemonic <strong>CRAB</strong>:</p>

    <div class="hand-drawn-box">
        <ul>
            <li><strong>C - Hyper<u>C</u>alcemia:</strong> Due to extensive bone resorption. Causes confusion, weakness, constipation, and stones.</li>
            <li><strong>R - <u>R</u>enal Insufficiency:</strong> Elevated creatinine due to cast nephropathy.</li>
            <li><strong>A - <u>A</u>nemia:</strong> Normocytic normochromic anemia due to marrow replacement by tumor cells and renal failure (low EPO). Causes fatigue and pallor.</li>
            <li><strong>B - <u>B</u>one Lesions:</strong> Bone pain (especially back pain), pathologic fractures, and vertebral collapse.</li>
        </ul>
        <p><em>*Note: Updated criteria (SLiM-CRAB) allow diagnosis with >60% marrow plasma cells, Light chain ratio >100, or MRI lesions even without symptoms.</em></p>
    </div>

    <p><strong>Other Features:</strong>
        <br>&bull; Recurrent infections (Pneumonia, Pyelonephritis).
        <br>&bull; Hyperviscosity syndrome (rare in IgG myeloma, common in IgA/IgM): Visual disturbances, neurological symptoms.
        <br>&bull; AL Amyloidosis (10% cases): Macroglossia, Carpal tunnel syndrome.</p>

    <hr>

    <h2>4. MORPHOLOGY (PATHOLOGY)</h2>

    <h3>A. Bone Marrow</h3>
    <ul>
        <li><strong>Cellularity:</strong> Hypercellular marrow.</li>
        <li><strong>Plasma Cells:</strong> <span class="highlight-green">> 10% Clonal Plasma Cells</span> (often >30%). They may be arranged in sheets, clusters, or interstitial infiltrates.</li>
        <li><strong>Microscopic Features of Neoplastic Plasma Cells:</strong>
            <ul>
                <li><strong>Perinuclear Halo:</strong> Clear zone near the nucleus (Golgi apparatus).</li>
                <li><strong>Eccentric Nucleus:</strong> "Cartwheel" or "Clock-face" chromatin pattern.</li>
                <li><strong>Binucleate/Multinucleate forms.</strong></li>
                <li><strong>Inclusion Bodies:</strong>
                    <ul>
                        <li><span class="highlight-neon">Russell Bodies:</span> Eosinophilic globules of immunoglobulin in the cytoplasm.</li>
                        <li><span class="highlight-neon">Dutcher Bodies:</span> Intranuclear inclusions (PAS positive).</li>
                        <li><strong>Mott Cells:</strong> Cells filled with multiple grape-like vacuoles (Grape cells).</li>
                        <li><strong>Flame Cells:</strong> Fiery red cytoplasm (seen in IgA myeloma).</li>
                    </ul>
                </li>
            </ul>
        </li>
    </ul>

    <h3>B. Peripheral Blood Smear</h3>
    <ul>
        <li><strong>Rouleaux Formation:</strong> RBCs stack like coins due to high serum protein (globulins) reducing negative charge (Zeta potential).</li>
        <li><strong>Plasma Cells:</strong> Occasionally seen (Plasma Cell Leukemia if >2,000/uL).</li>
        <li><strong>Anemia:</strong> Normocytic normochromic.</li>
    </ul>

    <h3>C. Gross Pathology (Bones)</h3>
    <ul>
        <li><strong>Punched-out Defects:</strong> Sharp, round, lytic defects seen in the skull ("Raindrop skull"), ribs, vertebrae, and pelvis. No reactive bone formation (sclerosis).</li>
    </ul>

    <hr>

    <h2>5. INVESTIGATIONS (LAB DIAGNOSIS)</h2>

    <div class="hand-drawn-box">
        <h3>Diagnostic Triad</h3>
        <ol>
            <li><strong>Bone Marrow:</strong> >10% clonal plasma cells.</li>
            <li><strong>Serum/Urine Protein:</strong> Monoclonal M-protein spike.</li>
            <li><strong>End Organ Damage:</strong> CRAB features.</li>
        </ol>
    </div>

    <ol>
        <li><strong>Serum Protein Electrophoresis (SPEP):</strong>
            <ul>
                <li>Shows a localized band/spike in the gamma-globulin region (<span class="highlight-neon">M-Spike</span> or M-Component).</li>
                <li>Most common: IgG (55%), followed by IgA (25%).</li>
            </ul>
        </li>
        <li><strong>Immunofixation:</strong> Confirms the type of heavy and light chain (e.g., IgG Kappa).</li>
        <li><strong>Urine Electrophoresis (UPEP):</strong> Detects Bence Jones Proteins (Free light chains).</li>
        <li><strong>Serum Free Light Chain Assay:</strong> Abnormal Kappa/Lambda ratio.</li>
        <li><strong>Biochemistry:</strong>
            <ul>
                <li>Hypercalcemia.</li>
                <li>Elevated Creatinine and Urea.</li>
                <li>Elevated Total Protein (with reversed Albumin/Globulin ratio).</li>
                <li><span class="highlight-green">Beta-2 Microglobulin:</span> Important prognostic marker (High levels = Poor prognosis).</li>
            </ul>
        </li>
        <li><strong>Radiology (Skeletal Survey):</strong> X-rays show punched-out lytic lesions. MRI/PET is more sensitive.</li>
    </ol>

    <hr>

    <h2 style="color: #d32f2f; border-color: #d32f2f;">IMPORTANT UNIVERSITY QUESTIONS</h2>

    <div class="qa-section">
        <h3>Q1: Define Multiple Myeloma. Describe its Pathogenesis and Clinical Features (CRAB).</h3>
        <p><strong>Introduction:</strong> Multiple Myeloma is a malignant neoplasm of plasma cells characterized by the production of monoclonal immunoglobulin (M-protein) and lytic bone lesions.</p>
        <p><strong>Body:</strong>
            <br><strong>Pathogenesis:</strong>
            <ul>
                <li><em>Genetic:</em> IgH translocations (14q32) and deletions (13q).</li>
                <li><em>Microenvironment:</em> IL-6 produced by stromal cells is the key growth factor.</li>
                <li><em>Bone Disease:</em> Myeloma cells activate RANKL, stimulating osteoclasts to resorb bone, leading to lytic lesions and hypercalcemia.</li>
            </ul>
            <br><strong>Clinical Features (CRAB):</strong>
            <ul>
                <li><strong>C:</strong> Calcium elevation (Hypercalcemia) &rarr; Confusion, weakness.</li>
                <li><strong>R:</strong> Renal impairment &rarr; Cast nephropathy (Bence Jones proteins).</li>
                <li><strong>A:</strong> Anemia &rarr; Fatigue.</li>
                <li><strong>B:</strong> Bone pain/Lesions &rarr; Pathologic fractures, punched-out lytic lesions.</li>
            </ul>
        </p>
        <p><strong>Conclusion:</strong> Diagnosis requires demonstrating marrow plasmacytosis (>10%), M-protein spike, and end-organ damage.</p>
    </div>

    <div class="qa-section">
        <h3>Q2: Describe the Laboratory Findings and Morphology of Multiple Myeloma.</h3>
        <p><strong>Introduction:</strong> Lab diagnosis hinges on demonstrating the monoclonal protein and the proliferation of atypical plasma cells.</p>
        <p><strong>Body:</strong>
            <br><strong>1. Peripheral Smear:</strong>
            <ul>
                <li><strong>Rouleaux formation</strong> (Coin stacking of RBCs) due to hypergammaglobulinemia.</li>
                <li>Leukoerythroblastic picture may be seen.</li>
            </ul>
            <br><strong>2. Bone Marrow:</strong>
            <ul>
                <li>Hypercellular with >10% plasma cells.</li>
                <li><em>Morphology:</em> Binucleate forms, eccentric nuclei, perinuclear halo. Presence of <strong>Russell bodies</strong> (cytoplasmic), <strong>Dutcher bodies</strong> (intranuclear), and <strong>Mott cells</strong> (grape-like).</li>
            </ul>
            <br><strong>3. Electrophoresis:</strong>
            <ul>
                <li>Serum: Tall, narrow <strong>M-spike</strong> in the gamma region.</li>
                <li>Urine: Bence Jones proteinuria.</li>
            </ul>
        </p>
        <p><strong>Conclusion:</strong> Elevated Beta-2 Microglobulin and Albumin levels are used for staging (ISS system).</p>
    </div>

</div>


</body>
</html>